ADAG SEC Filings: 8-K, 10-Q, S-3 & 424B – Adagene

Financials

TYPE

HEADLINE

FILED AT

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 1, 2026

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 24, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 29, 2024

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 28, 2023

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 26, 2022

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 28, 2021

News

TYPE

HEADLINE

FILED AT

6-K

NEWAdagene Completes Enrollment in Phase 2 Trial of Muzastotug and KEYTRUDA Combination for Colorectal Cancer

Nov 9, 2026

6-K

Adagene Inc. Announces Resignation of Executive Director of Finance

Sep 25, 2026

6-K

Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Sep 22, 2026

6-K

Adagene Announces Third Arc Bio Selects First Lead Candidate Under Amended Strategic Collaboration

Sep 10, 2026

6-K

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Sep 9, 2026

6-K

Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates

Aug 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Apr 2, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: Leerink Partners, LifeSci Capital, Lucid Capital Markets

Apr 2, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 10,625,000

Jan 9, 2026

424B5

May 2025 ATM

May 30, 2025

424B5

ATM | Offering amount: $100,000,000

Mar 29, 2024

424B4

7,354,000 American Depositary Shares-

Feb 10, 2021

Registrations

TYPE

HEADLINE

FILED AT

F-3

SHARE RESALE REGISTRATION

Oct 31, 2025

F-3/A

SHARE RESALE REGISTRATION | Offering amount: $200,000,000 | Amount sold to date: $0

May 23, 2025

F-3

May 2025 SHELF & ATM | Amount sold to date: $0

May 9, 2025

F-3/A

SHELF | Offering amount: $200,000,000.00 | Amount sold to date: $0.00 EFFECTIVE

May 20, 2022

F-3/A

SHELF | Offering amount: $200,000,000.00 | Amount sold to date: $0.00 EFFECTIVE

May 13, 2022

F-3

SHELF | Offering amount: $200,000,000.00 | Amount sold to date: $0.00 EFFECTIVE

Apr 26, 2022

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

GU CHUNFANG (Reporting)

Oct 2, 2026

Tam Man Kin (Reporting)

Sep 25, 2026

Luo Peter (Reporting)

Sep 17, 2026

144/A

Form 144/A - Report of proposed sale of securities: [Amend]

Aug 20, 2026

144

Form 144 - Report of proposed sale of securities

Aug 19, 2026

DO CUONG V (Reporting)

Aug 18, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 12, 2026

CORRESP

Form CORRESP - Correspondence

Jan 7, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 2, 2025

CORRESP

Form CORRESP - Correspondence

May 28, 2025

CORRESP

Form CORRESP - Correspondence

May 23, 2025

LETTER

Form UPLOAD - SEC-generated letter

May 21, 2025

Adagene Inc. ADAG · SEC Filings